Skip to main content
. 2024 Sep 5;15:1432799. doi: 10.3389/fimmu.2024.1432799

Table 4.

Comparison of allogeneic vs. autologous CAR T-Cell therapies.

Feature Allogeneic CAR T-Cell Therapy Autologous CAR T-Cell Therapy
Source of T Cells T cells are derived from healthy donors. T cells are derived from the patient themselves.
Manufacturing Time Shorter preparation time, as cells are pre-manufactured. Longer preparation time, cells must be collected and engineered per patient.
Cost Potentially lower cost due to the "off-the-shelf" nature. Higher cost due to the personalized manufacturing process.
Risk of Rejection Higher, due to potential immune reaction against donor cells. Lower, as the cells are the patient’s own.
Risk of GVHD (Graft vs. Host Disease) Present, requires genetic modifications to reduce risk. Absent, as the cells originate from the patient.
Scalability High, as cells can be produced in large batches. Low, each batch is patient specific.
Availability Immediate availability for use in acute settings. Requires weeks to months for cell preparation.
Clinical Applications May be limited by immune compatibility issues. Broad applicability, especially in approved indications.